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ibbon synapses in retinal sensory neurons maintain
large pools of readily releasable synaptic vesicles.
This allows them to release several hundreds of ves-
icles per second at every presynaptic release site. The
molecular components that cause this high transmitter re-
lease efﬁciency of ribbon synapses are unknown. In the
present study, we identiﬁed and characterized two novel
vertebrate complexins (CPXs), CPXs III and IV, that are the
R
 
only CPX isoforms present in retinal ribbon synapses.
CPXs III and IV are COOH-terminally farnesylated, and,
like CPXs I and II, bind to SNAP receptor complexes.
CPXs III and IV can functionally replace CPXs I and II, and
their COOH-terminal farnesylation regulates their synap-
tic targeting and modulatory function in transmitter re-
lease. The novel CPXs III and IV may contribute to the
unique release efﬁcacy of retinal sensory neurons.
 
Introduction
 
Sensory neurons in the retina use graded potentials to transmit
sensory information. By this mechanism, they are able to con-
tinuously adjust their synaptic output to changing inputs and
thus optimize information transfer (Parsons and Sterling,
2003). As the synaptic output of sensory neurons is initiated by
exocytotic neurotransmitter release from synaptic vesicles, its
continuous adjustment over a physiologically relevant range
requires that large numbers of synaptic vesicles fuse with the
plasma membrane at very high rates (Parsons and Sterling,
2003). In the retina, the photoreceptor cells and their second-
order neurons, the bipolar cells, can release several thousands
of synaptic vesicles per second. In terms of individual release
sites, this represents an exocytosis rate of several hundred vesi-
cles per second (Heidelberger et al., 1994; Parsons et al., 1994;
Rieke and Schwartz, 1996; von Gersdorff et al., 1996). This
high rate of release exceeds that of conventional synapses by a
factor of 30 (Stevens and Tsujimoto, 1995), and is made possi-
ble because sensory neurons have large numbers of primed and
readily releasable vesicles that can be exocytosed via a rapid
release mechanism.
A main factor contributing to the extreme exocytotic per-
formance of sensory neurons is the organization of their release
sites, or active zones. Conventional active zones at glutamater-
gic synapses in the mammalian central nervous system are
characterized by a flat, electron-dense structure that is associ-
ated with the presynaptic plasma membrane and from which
fuzzy electron-dense projections emanate into the surrounding
cloud of synaptic vesicles. In contrast, presynaptic active zones
in retinal photoreceptors and bipolar cells, and also in inner ear
sensory neurons and in neurons within the pineal gland, contain
a specialized plate-like organelle, the ribbon. Each ribbon is
anchored to the presynaptic plasma membrane in close vicin-
ity to voltage-gated Ca
 
2
 
 
 
 channel clusters, and tethers some
100 synaptic vesicles via short filamentous connections. It is
thought that the vesicles tethered to the ribbon are readily re-
leasable and that they release their transmitter content by
compound fusion (Parsons and Sterling, 2003). Anchored rib-
bons are essential for normal photoreceptor ribbon synaptic
transmission (Dick et al., 2003).
Unique molecular constituents are likely to be responsible
for the extraordinary morphological and functional characteristics
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of retinal ribbon synapses. However, only very few ribbon syn-
apse specific proteins have been identified. One such protein is
RIBEYE, a structural component of ribbons with unknown
function (Schmitz et al., 2000). In addition, Ca
 
2
 
 
 
 channels
(L-type at ribbon synapses and N-, P/Q-, or R-type at conven-
tional synapses; Heidelberger and Matthews, 1992; Nachman-
Clewner et al., 1999; Morgans, 2001), syntaxins (syntaxin 3 at
ribbon synapses and syntaxin 1 at conventional synapses; Mor-
gans et al., 1996), and synapsins (synapsins I and II are absent
from ribbon synapses; Mandell et al., 1990) are differentially
distributed between ribbon synapses and conventional synapses.
Apart from above examples, ribbon synapses contain
largely the same proteins as conventional synapses. This also
applies to the SNARE proteins synaptosomal-associated protein
of 25 kD (SNAP-25) and VAMP/synaptobrevin 2, which to-
gether with syntaxins 1, 2, or 3 mediate the actual synaptic vesi-
cle fusion reaction with the plasma membrane (Jahn et al.,
2003). SNARE complex function at synapses is regulated by a
number of interacting proteins which are responsible for the
characteristic spatial restriction, speed, and Ca
 
2
 
 
 
 dependence of
neurotransmitter release. Among these SNARE-regulating pro-
teins are complexin (CPX) I and CPX II, which regulate a late
step in the release process, most likely by stabilizing SNARE
complexes and thus maintaining synaptic vesicles in a highly re-
lease competent state (Reim et al., 2001; Chen et al., 2002).
We show here that the essential SNARE regulators CPXs
I and II are not present at retinal ribbon synapses. Instead, rib-
bon synapses in the retina contain two members of a novel
mammalian CPX subfamily, CPX III and CPX IV, which ex-
hibit unusual structural and functional characteristics.
 
Results
 
Structure and conservation of CPX 
isoforms
 
Using protein profile searches, we identified two genes in cur-
rent genomic databases (CELERA) which encode two novel
CPXs, CPX III and CPX IV. We assembled the complete hu-
man CPXs III and IV coding sequences from genomic se-
quence data (CELERA: GA_x5YUV32W5LP for CPX III and
GA_x5YUV32VUQQ for CPX IV), then designed PCR prim-
ers, and amplified the full-length human CPXs III and IV cDNAs
from brain cDNA. Based on the human sequence, the cDNAs of
murine CPXs III and IV were PCR amplified from mouse brain
cDNA. The cloned cDNA sequences were almost identical to
the sequences deduced from genomic data and were used for
subsequent comparative sequence analyses (Fig. 1 A). Data-
base searches revealed no evidence for additional CPX genes
in the human genome. Human and murine CPXs III and IV
cDNA sequences were deposited in GenBank (GenBank/
Figure 1. Comparison of primary structures of different CPXs
in different species. (A) Amino acid sequences of CPXs are
shown in single letter amino acid code and aligned for maxi-
mal homology. Residues that are identical in the majority of se-
quences are shown on black background, and residues that
are similar are shaded (similarity groups: F, Y, W; I, L, V, M;
H, R, K; D, E; G, A; T, S; N, Q). The core helix (aa 48–70 of
mCPX I) mediating SNARE complex binding of CPX I is
marked with a hatched bar. ag, Anopheles gambia; ce, Cae-
norhabditis elegans; ci, Ciona intestinalis; dm, Drosophila
melanogaster; h, human; hm, Hirudo medicinalis; lp, Loligo
pealeii; m, mouse; nj, Narke japonica; xl, Xenopus laevis; Gen-
Bank/EMBL/DDBJ accession nos. of the novel CPXs are:
AY28650, hCPX III; AY286502, hCPX IV; AY264290, mCPX
III; AY264291, mCPX IV. (B) Phylogenetic tree illustrating the
homology between different CPXs. Abbreviations as in A. 
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EMBL/DDBJ accession nos. AY286501 [hCPX III],
AY286502 [hCPX IV], AY264290 [mCPX III], and
AY264291 [mCPX IV]).
Alignment of murine amino acid sequences revealed that
the two new members of the CPX family are highly homolo-
gous (58% identity) to each other, but show only limited ho-
mology with CPXs I and II (24–28% identity; Fig. 1 B). Like
CPXs I and II, CPXs III and IV are small, highly charged mol-
ecules, containing 158 residues (17.6 kD) and 160 residues
(18.3 kD), respectively. In contrast to CPXs I and II, CPXs III
and IV contain a CAAX-box motif at their COOH termini (Fig.
1 A) which represents a consensus sequence for posttransla-
tional prenylation (Zhang and Casey, 1996). Comparison of
mouse and human CPX sequences showed that the respective
CPXs III and IV orthologues are very similar to each other,
with over 91% identity at the amino acid level. The corre-
sponding sequence identity between murine and human CPXs I
and II orthologues is 97 and 100%, respectively. Several inver-
tebrate species express CPXs that contain CAAX-boxes but are
otherwise more similar to murine and human CPXs I and II
(Fig. 1, A and B).
 
Expression pattern of CPX mRNAs
 
To analyze the expression pattern of CPXs III and IV mRNAs,
we hybridized blots loaded with poly(A)
 
 
 
 RNA from rat heart,
brain, spleen, lung, liver, skeletal muscle, kidney, and testis
with full-length mouse CPXs III and IV cDNA probes. No sig-
nals were detected on these blots.
We next searched EST databases for CPX sequences and
their tissue origin. All identified mCPX IV ESTs were derived
from eye or retina. Likewise, mCPX III ESTs were mostly de-
rived from eye or retina, but also from whole brain or visual
cortex. To test if the new CPXs III and IV are preferentially ex-
pressed in retina, we compared the expression pattern of
mRNAs of all known CPX isoforms in rat brain and retina by
hybridizing blots loaded with poly(A)
 
 
 
 RNA from whole rat
brain and rat retina at high stringency using full-length rat CPX I
(GenBank/EMBL/DDBJ accession no. U35098), rat CPX II
(GenBank/EMBL/DDBJ accession no. U35099), mouse CPX
III, and mouse CPX IV cDNA probes. CPXs I and II mRNAs
were found in brain and retina whereas CPXs III and IV tran-
scripts were only detectable in retina (Fig. 2 A).
As mentioned above, the CPXs III and IV cDNAs were
amplified from brain cDNA and the mouse EST search
showed that there must be transcripts of CPX III in the murine
and human brain, but we were not able to detect CPX III
mRNA in Northern blots with rat brain mRNA. This indicates
that the mCPX III gene is either expressed at very low levels
or in a small population of cells in the brain, or for only a brief
period of time during brain development. To distinguish be-
tween these possibilities, we performed in situ hybridization
experiments on mouse brain sections using radiolabeled anti-
sense oligonucleotides as probes. As expected from RNA blot
data and EST database searches, CPX IV mRNA was not de-
tectable on brain sections (unpublished data). In contrast, CPX
III mRNA was found in many regions of the brain (Fig. 2 B).
Most importantly, pyramidal cells in the CA regions of the
hippocampus as well as granule cells in the dentate gyrus ex-
press CPX III mRNA, as well as CPXs I and II mRNAs. In
cerebellum, CPX I, II, and III mRNAs were detected in the
granule cell layer, and CPXs I and III mRNAs were found in
the Purkinje cell layer.
 
Expression pattern of CPX proteins
 
For the detection of CPXs III and IV proteins, we generated
polyclonal antisera to the human and mouse isoforms using re-
combinant His
 
6
 
-tagged full-length proteins as antigens. The an-
tisera showed only very weak cross reactivity with the respec-
tive homologous isoform (i.e., CPX III vs. CPX IV), as
determined by Western blots of HEK293 cells overexpressing
EGFP-tagged full-length mouse CPXs. No cross reactivity of
either antiserum with CPX I or CPX II was observed (Fig. S1,
available at http://www.jcb.org/cgi/content/full/jcb.200502115/
DC1). The antisera raised against the human proteins cross re-
acted with the respective mouse and rat CPXs III and IV (Fig. 3).
The weak cross reactivity of our antisera to CPX III (vs. CPX
Figure 2. CPX mRNA expression in brain and retina. (A) Blots containing
poly(A)
 -RNA from rat brain and retina, hybridized at high stringency
with uniformly labeled full-length cDNA probes for rCPXs I or II, or mCPXs
III or IV, and exposed to film for 20 h. (B) Negative X-ray film images
showing the distribution of CPXs I, II, and III in adult mouse brain (left),
and high magnification bright field images of emulsion dipped slices
where silver grains (bright areas) represent the distribution of CPXs I, II,
and III in adult mouse hippocampus (middle) and cerebellum (right). Ce,
cerebellum; Co, cortex; Hi, hippocampus; IC, inferior colliculus; OB, olfac-
tory bulb; Th, thalamus. Bar: (left) 2 mm and (middle and right) 0.25 mm. 
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IV) and CPX IV (vs. CPX III) that was observed in Western
blot experiments (Fig. S1) does not interfere with their ability to
selectively label their respective antigens in immunocytochem-
ical experiments in retina. The two antisera produce specific
and distinct labeling patterns, indicating their CPX isoform
specificity (Figs. 4 and 5).
CPXs I and II were found in rat brain and retina, but with
higher expression in brain (Fig. 3 A), CPX III was most
strongly expressed in rat retina and much less in rat brain (Fig.
3 B), and CPX IV was only detectable in retina (Fig. 3 B).
Apart from the retina, CPX III was detected in hippocampus,
olfactory bulb, cortex, inferior colliculus, thalamus, and stria-
tum (Fig. 3 C). In Western blots using mouse central nervous
system homogenates, we detected CPX III also in the cerebel-
lum (not depicted).
Like CPXs I and II, CPX III protein expression during
mouse brain development is first detectable at P6 and in-
creases to reach a plateau at 
 
 
 
20 d after birth when most syn-
apses have been formed (Fig. 3 D). Analysis of rat cortical
subcellular fractions showed that CPXs I and II are soluble
while CPX III is associated with both, the cytosolic synaptic
fraction (LS2) and membranes, where it is enriched in the light
membrane pellet (P3) but also detectable in the crude synaptic
vesicular fraction (LP2), and in synaptic membranes (LP1 and
SPM; Fig. 3 E).
Figure 3. CPX protein expression in different tissues, brain regions,
developmental stages, and brain subcellular fractions. Homogenates from
the indicated rat organs (A and B), rat brain regions (C), brains from mice
of different ages (D), and rat cortex subcellular fractions (E) were ana-
lyzed by Western blotting using specific antibodies to the indicated pro-
teins (arrows). The two CPX III panels in E show a short (bottom) and long
(top) exposure of the same blot. Developmental stages were designated as
follows: E, embryonic day; P, postnatal day. Subcellular fractions were
designated as described in Materials and methods.
Figure 4. Differential distribution of CPXs I/II, III, and IV in the mouse
retina. (A–C) Confocal micrographs of vertical sections through mouse ret-
ina double labeled for the different CPXs (red) and VGLUT1 (green), as a
marker for the glutamatergic synaptic terminals of photoreceptors and bi-
polar cells. The micrographs to the right show high power views of areas
of the OPL and the IPL. (A) Somata of amacrine cells in the INL and of
amacrine and ganglion cells in the GCL show CPX I/II immunoreactivity.
The processes of CPX I/II labeled amacrine cells stratify in three bands in
the IPL. In the OPL, horizontal cell processes are weakly CPX I/II immu-
noreactive (arrows). There is no colocalization of CPX I/II and VGLUT1.
(B) Somata of amacrine cells in the INL and their processes stratifying in a
broad band in the IPL, abutting the INL, are labeled for CPX III. The large
CPX III immunoreactive structures in the IPL, close to the GCL, and in the
OPL, are bipolar and cone photoreceptor terminals (arrows), respectively,
as seen in the double labeling with VGLUT1. (C) CPX IV and VGLUT1
colocalize in the IPL and the OPL, indicating the expression of CPX IV in bi-
polar and photoreceptor cell terminals. OPL, outer plexiform layer (synaptic);
INL, inner nuclear layer; IPL, inner plexiform layer (synaptic); GCL, gan-
glion cell layer. Bar, 20  m. 
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Distribution of CPXs in the mouse retina
 
To characterize the cellular and synaptic expression of CPXs in
mouse retina, we performed immunocytochemical experiments
in which we combined labeling of the different CPXs with mark-
ers of individual types of retinal neurons and their synapses.
Initially, we combined each anti-CPX antiserum with
an antibody against the vesicular glutamate transporter 1
(VGLUT1; Fig. 4), which specifically marks the glutamatergic
synaptic terminals of photoreceptors in the outer plexiform
layer (OPL) and of bipolar cells in the inner plexiform layer
(IPL) of mouse retina (Johnson et al., 2003; Sherry et al.,
2003). The antiserum against CPX I/II (Fig. 4 A) labels somata
of amacrine cells in the inner nuclear layer (INL) and somata of
displaced amacrine cells and of ganglion cells in the ganglion
cell layer (GCL). The CPX I/II-stained processes of amacrine
cells stratify in the IPL in three bands of strong fluorescence in-
tensity (Fig. 4 A). The lack of colocalization between CPX I/II
and VGLUT1 in the IPL (Fig. 4 A) indicates that CPXs I and II
are present at amacrine cell synapses and not at bipolar cell rib-
bon synapses. Most amacrine cell synapses in the IPL are con-
ventional GABAergic and glycinergic synapses. Double label-
ing experiments, in which the antisera against CPX I/II were
combined with antibodies against GABA or glycine, showed
that populations of GABAergic but not glycinergic amacrine
cells express CPX I/II (Fig. S2, available at http://www.jcb.
org/cgi/content/full/jcb.200502115/DC1). The OPL contains
the glutamatergic ribbon synapses of the photoreceptors. Like
in the IPL, CPXs I/II do not colocalize with VGLUT1 in the
OPL and thus are absent from photoreceptor ribbon synapses
(Fig. 4 A). Only the primary processes of horizontal cells are
weakly CPX I/II immunoreactive (Fig. 4 A).
CPX III immunoreactivity (Fig. 4 B) is present in both
plexiform layers of the retina, the IPL and the OPL. In addition,
somata of amacrine cells in the INL are labeled. In the IPL, the
broad CPX III immunoreactive band abutting the INL, is formed
by processes of amacrine cells, which do not contain VGLUT1
(Fig. 4 B). Double labeling experiments in which the antisera
against CPX III were combined with antibodies against GABA
or glycine, showed that, unlike CPXs I/II, CPX III is expressed
in subpopulations of glycinergic amacrine cells (Fig. S3, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200502115/DC1).
GABAergic amacrine cells, which are labeled for CPX III, are
very rarely found. The second broad immunoreactive band in the
IPL, close to the GCL, consists of bipolar cell terminals, which
are double labeled for CPX III and VGLUT1 (Fig. 4 B). Double
labeling with an antibody against PKC
 
 
 
, identifies these termi-
nals as rod bipolar cell terminals (Fig. S3). In the OPL, the large
synaptic terminals of cone photoreceptors are double labeled for
VGLUT1 and CPX III (Fig. 4 B).
CPX IV immunoreactivity is present in both synaptic layers
of the retina, the IPL and OPL. Here, it colocalizes with
VGLUT1 (Fig. 4 C). The distribution of CPX IV immunoreactiv-
ity in the two synaptic layers differs from that of CPX III. In the
OPL, many smaller photoreceptor terminals are strongly labeled
for CPX IV, and in the IPL, putative cone bipolar cell terminals,
which are located in a broader band approximately in the middle
of the IPL, are CPX IV immunoreactive (Fig. 4 C). CPX IV stain-
ing in the IPL does not colocalize with VGLUT3, which has been
found in a subset of amacrine cells in mouse retina (Haverkamp
and Wassle, 2004; Johnson et al., 2004; not depicted).
These data show that CPXs I/II are expressed at conven-
tional amacrine cell synapses, whereas CPX IV is present at
photoreceptor and bipolar cell ribbon synapses. Both types of
retinal synapses, ribbon and conventional, contain CPX III.
A comparison of the results of double labeling for CPX
III/VGLUT1 and for CPX IV/VGLUT1 indicates that different
types of bipolar cells and of photoreceptor cells express the two
CPXs (Fig. 4, B and C). To examine this in more detail in pho-
toreceptor cells and their synapses, we performed experiments
in which we incubated retinal sections with peanut agglutinin
(PNA) together with the antiserum against CPX III (Fig. 5, A–C)
or CPX IV (Fig. 5, D–F). The OPL of the retina contains the
terminals and synapses of the rod and cone photoreceptors, and
PNA specifically marks cone photoreceptor terminals (Blanks
and Johnson, 1984). Strong CPX III immunoreactivity is
present in the cone photoreceptor terminals, and the rod photo-
receptor terminals are only weakly CPX III immunoreactive
(Fig. 5, A–C). CPX IV, on the other hand, is strongly expressed
in the rod photoreceptor terminals and absent from the cone
photoreceptor terminals (Fig. 5, D–F). Costaining of CPXs III
Figure 5. Differential expression of CPXs III and IV by
photoreceptors and their synapses. (A–C) Confocal mi-
crographs of a vertical section through mouse retina dou-
ble labeled for CPX III (A, red) and PNA (B, green) as a
marker for cone photoreceptor terminals. As seen in the
merge of the two stainings, CPX III is strongly expressed
in the large cone photoreceptor terminals (C, arrows),
and only weakly in the small rod photoreceptor terminals.
(D–F) Confocal micrographs of a vertical section through
mouse retina double labeled for CPX IV (D, red) and PNA
(E, green). The terminals of cone photoreceptors are de-
void of CPX IV staining, which is present in the rod photo-
receptor terminals (F). (G and H) Confocal micrographs
of vertical sections through mouse retina double labeled
for CPX III (G, red) and Bassoon (G, green) and for CPX
IV (H, red) and Bassoon (H, green). The merge of the
stainings confirms the presence of CPX III at cone (G,
arrows) and rod ribbon synapses, and of CPX IV at rod
ribbon synapses (H). The asterisk in H marks an unspe-
cifically stained blood vessel. Bars, 5  m. 
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or IV with antibodies to Bassoon, a marker of all photoreceptor
ribbon synapses (Brandstätter et al., 1999), also indicates the
presence of CPX III at ribbon synapses of cone and rod photo-
receptors and of CPX IV at rod photoreceptor ribbon synapses
only (Fig. 5, G and H).
 
Farnesylation of CPXs III and IV
 
CPXs III and IV carry CAAX-box motifs at their COOH ter-
mini (Fig. 1 A) which can be used for stable posttranslational
prenylation by addition of either a farnesyl (15-carbon) or a
geranylgeranyl (20-carbon) moiety at the cysteine residue, sub-
sequent endoproteolytic cleavage of the AAX tripeptide, and
carboxymethylation of the COOH-terminal cysteine residue.
The methionine at the last position of the CAAX-box in CPXs
III and IV likely causes farnesylation (Zhang and Casey, 1996).
To verify that the CAAX-boxes of CPXs III and IV are used
for farneslyation in vivo, HEK293 cells were transfected with
expression vectors encoding either wild-type (wt) EGFP-CPXs
III and IV fusion proteins or mutant EGFP-CPXs III and IV fu-
sion proteins in which the cysteine residues of the CAAX-
boxes were replaced by serin residues (C156S in CPX III and
C158S in CPX IV). Cells were labeled with the prenyl precur-
sor [
 
14
 
C]mevalonate and harvested, and proteins were solubi-
lized and immunoprecipitated. Samples were analyzed by
SDS-PAGE and immunoblotting using an mAb to EGFP, as
well as by autoradiography. The immunoblot shows that all
proteins were expressed and immunoprecipitated at equal lev-
els (Fig. 6, bottom), but autoradiography of gels showed that
only wt proteins were 
 
14
 
C-labeled (Fig. 6, top), indicating that
CPXs III and IV are farnesylated in vivo.
Because the posttranslational attachment of prenyl groups
is important for targeting proteins to membranes (Zhang and
Casey, 1996), we studied the distribution of wt CPXs I, II, III,
and IV as well as mutant CPX III-C156S and CPX IV-C158S in
HEK293 cells. Initially, we used the EGFP-CPX III and EGFP-
CPX IV expression constructs mentioned above, as well as ex-
pression constructs encoding full-length CPXs I and II with
COOH-terminally fused EGFP. We found that CPXs I, II, and
the mutant CPXs III and IV were diffusely distributed in the
cytoplasm and the nucleus whereas wt CPXs III and IV were
partially plasma membrane associated, present in granular
structures in the cytosol, and excluded from the nucleus
(Fig. S4 A, available at http://www.jcb.org/cgi/content/full/
jcb.200502115/DC1). To circumvent a possible artifact caused
by the EGFP-tag we next overexpressed the untagged variants
of all CPXs, homogenized the cells, and separated the soluble
and membrane-bound pools by centrifugation. Western blot
analyses showed that CPXs I and II as well as the main fraction
of farnesylation-deficient CPXs III and IV are soluble, whereas
wt CPXs III and IV were mainly found in the membranous
pellet fraction (Fig. S4 B).
To examine the distribution of the different CPX iso-
forms in neurons and to test if farnesylation of CPXs III and IV
leads to membrane association and affects subcellular localiza-
tion, primary hippocampal neurons were transfected with the
EGFP-tagged CPX constructs described above. Cells were
fixed with paraformaldehyde and immunolabeled with an mAb
to synaptophysin. In mature cultures analyzed at 14 d in vitro
(DIV), CPX I-EGFP and CPX II-EGFP transfected at 4 DIV
were distributed diffusely throughout axonal processes and
were only weakly enriched in areas that specifically colocal-
ized with the presynaptic marker synaptophysin (Fig. 7). In
contrast, EGFP-CPX III and EGFP-CPX IV were enriched in
puncta which were characteristic of presynaptic terminals/vari-
cosities and which colocalized with synaptophysin (Fig. 7).
Such puncta were not found in processes positive for the den-
dritic marker MAP2, but were often found along MAP2-posi-
tive processes (not depicted), as expected of presynaptic ter-
minals. In contrast, EGFP-CPX III-C156S and EGFP-CPX
IV-C158S showed the same diffuse distribution as CPX I-EGFP
and CPX II-EGFP (Fig. 7). In immature neurons transfected
with constructs expressing EGFP-CPXs III and IV at 8 DIV
and immunostained for the trans-Golgi marker TGN38 at 9
DIV, CPXs III and IV were enriched in the trans-Golgi net-
work (unpublished data).
These data indicate that CPXs III and IV are specifically
targeted to synaptic terminals in a farnesylation dependent
manner. This observation corroborates well with the finding
that CPX III is associated with both, the cytosolic synaptic
fraction and synaptic membranous compartments in the brain
(Fig. 2 E).
 
SNARE complex binding of novel CPXs
 
The formation of the synaptic SNARE complex between syn-
taxin 1 (or syntaxins 2 and 3), SNAP-25, and synaptobrevin/
VAMP 2 is a key step in synaptic vesicle exocytosis. CPXs I
and II regulate a late step in the transmitter release process
(Reim et al., 2001), most likely by binding to the SNARE com-
plex in an antiparallel manner and thereby stabilizing it (Chen
et al., 2002). The new CPX isoforms show only limited homol-
ogy with CPXs I and II (Fig. 1), but most of the conserved resi-
dues are found in the core region which forms the SNARE
complex binding 
 
 
 
-helix (aa 48–70), indicating that the novel
CPXs might also act as SNARE complex regulators.
Figure 6. In vivo farnesylation of CPXs III and IV. Transfected HEK293
cells coexpressing a mevalonate transporter and either wt EGFP-CPXs III or
IV (CPX III, CPX IV), or mutant EGFP-CPXs III or IV (CPX III-C156S, CPX IV-
C158S) were labeled with [
14C]mevalonate and harvested. Control cells
were only transfected with the mevalonate transporter. Whole cell lysates
as well as solubilized and immunoprecipitated proteins were analyzed by
Western blotting, using an mAb to EGFP (Western blot), and autoradiog-
raphy (Autoradiograph). The arrows indicate the EGFP-CPX–fusion proteins.
All proteins were expressed and precipitated (bottom) but only wt proteins
were 
14C-labeled (top). 
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To test whether the new CPX isoforms bind SNARE com-
plexes, cosedimentation assays were performed. GST-fusion
constructs encoding full-length rCPX I, mCPX III, and mCPX
IV in frame with GST were used for expression of recombinant
proteins in bacteria. Initially, recombinant GST-CPX–fusion
proteins were incubated with detergent extracts from rat brain
synaptosomes, and proteins bound to the GST-CPX beads were
analyzed by Western blotting. CPXs I and III bound similar
amounts of syntaxin 1, SNAP-25, and synaptobrevin 2 (Fig. 8
A), whereas CPX IV bound the three SNARE components only
weakly. Similar results were obtained when we used rat retina
extracts as the source of CPX binding proteins (Fig. 8 A). In ad-
dition to syntaxin 1, syntaxin 3, which is expressed by retinal
photoreceptors and bipolar cells, also bound to CPXs I and III.
In a third set of experiments, we used again rat retina extract as
protein source but washed with reduced stringency. As ex-
pected, we found again significant binding of syntaxins 1 and 3,
SNAP-25, and VAMP/synaptobrevin 2 to CPXs I and III,
whereas in the CPX IV pellets, only low levels of the SNARE
complex components were detected (Fig. 8 A).
These results indicate that all known CPXs interact with
SNARE complexes, but CPX IV has a lower SNARE complex
binding affinity than all other CPXs.
 
Function of CPXs III and IV
 
CPXs III and IV differ from CPXs I and II in structure and ex-
pression pattern, but bind SNARE complexes and may therefore
still play a role in neurotransmitter release that is equivalent to
that of CPXs I and II. To examine this possibility and to test
whether farnesylation of the novel CPXs influences their func-
tion, we used a knockout (KO) rescue approach. We compared
the different CPXs as well as the CPXs III and IV farnesyla-
tion mutants with respect to their ability to restore efficient
neurotransmitter release in CPX I/II double-deficient (CPX I/II
Figure 7. Distribution of CPXs III and IV in neurons.
Neurons transfected with expression vectors encoding
either wt CPX I-EGFP, CPX II-EGFP, EGFP-CPX III, EGFP-
CPX IV or farnesylation-deficient EGFP-CPX III-C156S,
and EGFP-CPX IV-C158S (all green), and immunostained
for synaptophysin (red) to mark presynaptic terminals
were analyzed by laser scanning confocal microscopy.
Wt CPXs III (top left) and IV (middle left) were concen-
trated in presynaptic structures of axons and colocalized
with synaptophysin, whereas mutant CPXs III (top right)
and IV (middle right) as well as wt CPXs I (bottom left)
and II (bottom right) showed a diffuse axonal distribution
with minor (CPXs I and II) or no (mutant CPXs III and IV)
presynaptic accumulation. Bars: (low magnification,
large images) 50  m; (high magnification, small images)
10  m. 
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double KO [DKO]) neurons. Whole-cell patch clamp record-
ings were performed on single hippocampal neurons cultured
on astrocyte microislands. In this preparation, neurons form
recurrent ‘autaptic’ synapses, which allows the simultaneous
measurement of various synaptic release modes originating
from the same population of synapses. We measured EPSCs
evoked by low frequency (0.2 Hz) action potentials and the
size of the readily releasable vesicle pool (RRP), as quantified
by integrating the transient inward current induced by a 4-s
application of external solution containing 500 mM sucrose
(Rosenmund and Stevens, 1996). From the EPSC charge and
the RRP charge, the vesicular release probability P
 
vr
 
 was cal-
culated as an indicator of the efficiency of Ca
 
2
 
 
 
-triggered
neurotransmitter release.
We showed previously that CPXs I and II regulate a late
step in the release process. In these studies, we found that CPX
I/II DKO neurons exhibited a 50% reduction in P
 
vr
 
 and a right
shift of the apparent Ca
 
2
 
 
 
 sensitivity of release, without
changes in the RRP (Reim et al., 2001). These defects were
fully rescued by Semliki Forest Virus mediated overexpression
of wt CPX I (Fig. 8 B). CPX I/II DKO neurons from four cul-
tures showed an average EPSC amplitude of 3.78 
 
 
 
 0.33 nA
(
 
n 
 
  
 
120) and an RRP of 0.81 
 
 
 
 0.06 nC (
 
n 
 
  
 
120), compared
with 7.30 
 
 
 
 0.53 nA (
 
n 
 
  
 
119, P 
 
  
 
0.0001) and 0.69 
 
 
 
 0.06 nC
(
 
n 
 
  
 
119, P 
 
  
 
0.13) in CPX I/II DKO neurons overexpressing
wt CPX I. P
 
vr
 
 was then calculated for each neuron. Upon rescue
with wt CPX I, the average P
 
vr
 
 was increased by 
 
 
 
90% from
0.069 
 
 
 
 0.005 (
 
n 
 
  
 
120) in CPX I/II DKO neurons to 0.129 
 
 
 
0.006 (
 
n 
 
  
 
119, P 
 
  
 
0.0001) in CPX I/II DKO neurons in-
fected with a virus expressing wt CPX I. These results vali-
date the rescue approach in CPX I/II DKO neurons via Sem-
liki Forest Virus mediated CPX overexpression because
overexpression of CPX I reconstituted a wt like P
 
vr
 
 in CPX I/II
DKO neurons.
We next analyzed the ability of CPXs III and IV to rescue
the reduced P
 
vr
 
 phenotype of CPX I/II DKO neurons. For that
purpose, CPX I/II DKO neurons were compared with CPX I/II
DKO neurons overexpressing wt CPX III or CPX III-C156S (Fig.
8 C) and wt CPX IV or CPX IV-C158S (Fig. 8 D). In these exper-
iments, CPX I/II DKO neurons overexpressing wt CPX I served
as a parallel-positive control. The average P
 
vr
 
 values obtained
are summarized in Fig. 8 E. Overexpression of wt CPX III (P
 
vr 
 
 
 
0.150 
 
 
 
 0.010, 
 
n 
 
  
 
61, P 
 
  
 
0.0001 compared with the CPX I/II
DKO) and CPX IV (P
 
vr 
 
 
 
 0.117 
 
 
 
 0.007, 
 
n 
 
  
 
62, P 
 
  
 
0.0001
compared with the CPX I/II DKO) fully rescued CPX I/II DKO
neurons, demonstrating that CPXs III and IV can act as positive
regulators of neurotransmitter release in hippocampal neurons, as
do CPXs I and II. Although the farnesylation of CPX III had little
impact on its function under conditions of Semliki Forest Virus
mediated overexpression (CPX III-C156S: P
 
vr
 
 
 
 
 
 0.126 
 
 
 
0.008, 
 
n 
 
  
 
56, P 
 
  
 
0.0001 compared with the CPX I/II DKO),
farnesylation of CPX IV was essential for its function as CPX IV-
C158S showed only weak rescue activity (P
 
vr
 
 
 
 
 
 0.083 
 
 
 
 0.007,
 
n 
 
  
 
65, P 
 
  
 
0.19 compared with the CPX I/II DKO).
These data show that CPXs III and IV are functionally
similar to CPXs I and II, and that farnesylation of CPX IV is
important for its function.
Figure 8. Characteristics of CPXs III and IV function. (A) Cosedimentation
assays with CPXs I, III, and IV. CPXs I, III, and IV were expressed as GST-
fusion proteins, immobilized on glutathione agarose, and incubated with
solubilized proteins from crude rat brain synaptosomes or rat retina ho-
mogenate. GST-CPX I and GST alone were used as positive and nega-
tive controls, respectively. Bound material was analyzed by Western
blotting using antibodies to the indicated proteins. Both, CPXs III and IV
bind to the SNARE complex, but the necessity to reduce the stringency of
the washing steps in order to demonstrate the interaction between the
SNARE complex and CPX IV indicates a lower binding affinity. (B–E)
Synaptic amplitudes, RRPs and vesicular release probability in
glutamatergic CPX I/II DKO neurons and CPX I/II DKO neurons rescued
by overexpression of CPXs I, III, or IV. Representative traces showing au-
taptic EPSCs and responses to hypertonic sucrose solution from a CPX
I/II DKO neuron (B, left), and CPX I/II DKO neurons rescued with wt CPX
I (C, right), wt CPX III (C, left), CPX III-C156S (C, right), wt CPX IV (D, left),
or CPX IV-C158S (D; right). Horizontal bar EPSC, 0.1 s; sucrose solu-
tion, 1.5 s. Vertical bar EPSC, 2 nA; sucrose solution, 1 nA. (E) Bar dia-
grams summarizing mean vesicular release probability for CPX I/II DKO
neurons and CPX I/II DKO neurons rescued with wt CPX I, wt CPX III,
CPX III-C156S, wt CPX IV, or CPX IV-C158S. Asterisks indicate P  
0.0001. Error bars indicate SEM.NOVEL COMPLEXINS IN RIBBON SYNAPSES • REIM ET AL. 677
Discussion
We characterized two new CPX isoforms, CPXs III and IV,
which form a novel mammalian subfamily of the CPX super-
family of SNARE regulators. A protein sequence comparison
between CPXs from different species revealed only limited
evolutionary conservation restricted to the region responsible
for SNARE complex binding (residues 48–70 of CPX I; Fig. 1 A).
In this region, residues that based on structural data (Chen et
al., 2002) are thought to be essential for the interaction with the
SNARE complex, and which we found to be essential for
SNARE complex binding in mutagenesis studies (unpublished
data), are conserved among isoforms and species (R
48, R
59, R
63,
K
69, and Y
70 of CPX I). Outside the SNARE complex binding
region, evolutionary conservation is limited to certain species
or one of the two CPX subfamilies. The accessory  -helix that
flanks the SNARE complex binding region NH2-terminally
(residues 30–47 in CPX I) is conserved among vertebrate
CPXs I and II and also insect CPXs I, but not in CPXs I from
other species or in the CPX III/IV subfamily. In the latter, it is
interrupted by a short, partially conserved sequence stretch.
Within the NH2 termini of CPXs, only one residue (F
3 in CPX
I) is conserved among all isoforms and species. In contrast, a
cluster of positive residues COOH-terminal of the SNARE
binding region is conserved in all members of the CPX I/II sub-
family, irrespective of the species, whereas it is absent from the
vertebrate CPX III/IV subfamily. The most striking difference
between the vertebrate CPX subfamilies is apparent at their
COOH terminus where CPXs III and IV carry an extension
with a functional CAAX-box farnesylation site that is absent in
CPXs I and II. This CAAX-box is not a recent evolutionary ac-
quisition because homologous sequences, in some cases also at
the end of COOH-terminal extensions, are present in many in-
vertebrate CPXs (Fig. 1 A). Apart from the CAAX-box, most
of the invertebrate CPXs are more similar to CPXs I and II than
to CPXs III and IV (Fig. 1 B). These data indicate that the ver-
tebrate CPXs originate from a common ancestor with a COOH-
terminal extension and a CAAX-box, both of which were lost
in vertebrate members of the CPX I/II subfamily after separa-
tion of the CPX I/II and CPX III/IV subfamilies.
Our expression studies in hippocampal neurons demon-
strate that farnesylation of CPXs III and IV at the CAAX-motif
mediates their specific presynaptic targeting (Fig. 7). Given the
evolutionary conservation of CAAX-motifs in CPXs (CAAM in
mouse and human CPXs III and IV, CAAS in Ciona intestinalis,
and CAAQ in Hirudo medicinalis, Drosophila melanogaster,
Anopheles gambia, and Loligo pealeii, all of which can be far-
nesylated; Zhang and Casey, 1996; Fig. 1 A), the same is likely
to be true for all other CPXs carrying this motif. The underly-
ing mechanism that causes synaptic targeting of prenylated
CPXs remains to be elucidated. It is possible that after synthe-
sis, lipidic or proteinaceous interactions at the level of the
trans-Golgi network recruit prenylated CPXs into distinct pre-
synapse-bound membrane compartments with characteristic
lipid and protein composition.
The main function of CPXs I and II in SNARE mediated
synaptic exocytosis is thought to involve stabilization of
SNARE complexes in a tight conformation, thus maintaining a
highly Ca
2  sensitive pool of readily releasable vesicles (Reim
et al., 2001; Chen et al., 2002). Our data indicate that the novel
CPX isoforms III and IV act as positive regulators of neu-
rotransmitter release, as do CPXs I and II in the central nervous
system, because CPXs III and IV bind to SNARE complexes
(Fig. 8 A) and their overexpression rescues the reduced Pvr phe-
notype of CPX I/II DKO neurons (Fig. 8, B–E). Interestingly,
farnesylation of CPX III has little impact on its function under
conditions of Semliki Forest Virus mediated overexpression
whereas farnesylation of CPX IV is essential for its rescue
function. It is likely that in the autaptic culture, the effect of
loss of CPX III farnesylation can be overcome by its high bind-
ing affinity to the SNARE complex (Fig. 8 A). However, the
binding affinity of CPX IV to the SNARE complex is much
lower than that of CPXs I, II, and III (Fig. 8 A). As a conse-
quence, its membrane association by farnesylation is a critical
parameter to reach sufficient local CPX IV concentration for
functional SNARE complex binding. This is demonstrated by
the almost complete lack of rescue activity of the farnesylation-
deficient CPX IV-C158S mutant (Fig. 8, B–E), and represents
a unique feature of the ribbon synapse specific CPX IV and its
role in controlling neurotransmitter release as compared with
other CPX family members.
Our data indicate that prenylation and synaptic targeting
of CPXs III and IV are of significant functional relevance. This
implies that the loss of the CAAX-box motif in CPXs I and II
must be compensated during evolution by other changes in
CPX I/II protein structure or the regulation of CPX I/II protein
expression in the many neurons of the central nervous system
that only express CPXs I and II. Indeed, CPXs I and II appear
to bind SNARE complexes with higher affinity than CPX IV
(Fig. 8 A). Our Northern blot data (Fig. 2 A) as well as the rel-
ative frequency of entries in current EST databases indicate
that CPXs I and II are expressed at much higher levels in brain
than CPX III. Both of these characteristics, i.e., higher expres-
sion levels in brain and high SNARE complex affinity, which
may be caused by the unique structural features of CPXs I and
II (e.g., in the region of the accessory  -helix and the positively
charged cluster COOH-terminal to the SNARE binding region),
could in principle contribute to a compensation of the disadvan-
tage that is caused by the loss of COOH-terminal farnesylation,
consequent lack of synaptic targeting, and free diffusibility in
neurons and their synaptic terminals.
COOH-terminal prenylation of CPXs is unlikely to inter-
fere significantly with SNARE complex binding in vivo be-
cause CPXs associate with the SNARE complex in an antiparal-
lel fashion (Chen et al., 2002) such that the prenylated COOH
terminus lies at the distal tip of the assembled trans SNARE
complex and not at the site of vesicle and plasma membrane
contact where v- and t-SNARE proteins are inserted into
membranes. A systematic mutagenesis study performed in our
laboratory indicates that only mutations of conserved CPX I
residues in the helical region that contacts the SNARE com-
plex interfere with SNARE complex binding. In contrast, muta-
tions in the NH2- and COOH-terminal sequences flanking the
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binding of CPX I (unpublished data). Thus, structural changes
in sequences outside of the actual SNARE complex binding sur-
face of CPXs do not interfere with SNARE complex binding,
and the same would be expected for the COOH-terminal farne-
sylation. That this is indeed the case is supported by our func-
tional rescue experiments on CPX I/II double-deficient neurons.
Our electrophysiological rescue experiments in neurons
show that the novel CPX isoforms act as positive regulators of
synaptic exocytosis, as do CPXs I and II, and that farnesylation
of CPX IV increases its activity. Thus, in addition to protein
expression levels, the efficacy of CPX action is defined by two
functional parameters, SNARE complex affinity and local
membrane concentration at the site of vesicle fusion, with the
latter parameter being positively modulated by COOH-termi-
nal farnesylation. The case of CPX IV exemplifies that these
two parameters can influence each other in a compensatory
manner as wt CPX IV (low SNARE complex affinity but high
local concentration at synaptic membranes due to farnesylation)
is functionally equivalent to CPX I (high SNARE complex af-
finity but no local enrichment due to the lack of farnesylation),
whereas the farnesylation-deficient CPX IV-C158S mutant is
functionally compromised (low SNARE complex affinity and
no local enrichment due to the lack of farnesylation; Fig. 8, B–E).
In view of these considerations, CPX III, in which high
SNARE complex affinity and COOH-terminal farnesylation
are combined, may represent a particularly effective CPX.
Thus, in terms of CPX function, ribbon synapses in the retina
have all possible advantages, i.e., the high CPXs III and IV
expression levels that are otherwise only found for CPXs I and
II at conventional synapses of the central nervous system, and
the added value of specific synaptic targeting and plasma
membrane anchoring.
CPX III is present at ribbon and conventional synapses in
the retina, whereas CPX IV seems to be solely expressed at rib-
bon synapses. The main CPX form at cone ribbon synapses is
CPX III, and at rod ribbon synapses CPX IV. Rods and cones ex-
hibit two kinetically distinct phases of release, a slow component,
which is similar in both cell types, and a fast component, which is
10 times faster in cones than in rods (Rabl et al., 2005). With
CPXs III and IV we have found constituents of the presynaptic
exocytotic machinery that are differentially expressed between
rod and cone ribbon synapses. It is possible that the high affinity
SNARE-binding, farnesylated CPX III isoform is responsible for
the very fast release component in cone photoreceptors.
We postulate that CPXs III and IV contribute to the
unique efficacy of transmitter release at retinal ribbon synapses.
Their expression and localization in retinal ribbon synapses and
their structure and targeting to synapses are characteristics of
CPXs III and IV that set them apart from the CPXs present in
conventional synapses. These features are also likely to convey
particularly efficient release properties to the brain synapses
that express CPX III.
Materials and methods
Cloning of human and mouse CPXs III and IV cDNAs
Protein profile searches identified two human genes with homology to
CPXs I and II in current genomic databases (CELERA database contigs
GA_x5YUV32W5LP and GA_x5YUV32VUQQ). The cDNAs of the new
human CPXs, which were designated CPX III and CPX IV, were amplified
by PCR from human brain QUICK-Clone cDNA (CLONTECH Laboratories,
Inc.). PCR products were subcloned into pCRII-TOPO (Invitrogen) and se-
quenced using the dideoxy chain termination method with dye terminators
on a 373 DNA sequencer (Applied Biosystems). Using primers designed
on the basis of the human cDNA sequences of CPXs III and IV, the corre-
sponding mouse cDNAs were amplified from mouse brain QUICK-Clone
cDNA (CLONTECH Laboratories, Inc.), subcloned and sequenced as
described above.
Northern blots
Rat multiple tissue RNA blots (CLONTECH Laboratories, Inc.) were used to
analyze the distribution of CPXs III and IV mRNAs. Poly(A)
  RNA from rat
brain and retina was isolated using the Oligotex Direct mRNA Midi/Maxi
Kit (QIAGEN). 2  g poly(A)
  RNA from each tissue were separated on a
denaturing formaldehyde agarose gel and blotted to nitrocellulose mem-
brane using standard protocols. Membranes were hybridized at high strin-
gency with uniformly labeled probes derived from rCPX I (GenBank/
EMBL/DDBJ accession no. U35098), rCPX II (GenBank/EMBL/DDBJ ac-
cession no. U35099), mCPX III (GenBank/EMBL/DDBJ accession no.
AY264290), and mCPX IV cDNAs (GenBank/EMBL/DDBJ accession no.
AY264291) followed by autoradiography.
In situ hybridization
In situ hybridization experiments were performed as described previously
(Augustin et al., 1999). Antisense oligonucleotides representing the fol-
lowing sequences were chosen as probes: bp 34–78 of rCPX I cDNA, bp
50–94 of rCPX II cDNA, bp 115–151 of mCPX III cDNA, and bp 238–
282 of mCPX IV cDNA. Sections were viewed with an axiophot micro-
scope (objectives: 20  PlanNeofluar 0.5 NA, and 40  PlanNeofluar
0.75 NA; Carl Zeiss MicroImaging, Inc.) and images were captured with
a digital camera (Camedia C3030 Zoom; OLYMPUS) using the Camedia
Master software.
Generation of antibodies against CPXs III and IV
Polyclonal antisera directed against CPXs III and IV were generated with
His-tagged fusion proteins as antigens (Eurogentech). Recombinant full-
length His6-CPXs III and IV fusion proteins were generated by using the
expression plasmids pET-28a-mCPX III and pET-28a-mCPX IV (full-length
mouse CPXs III and IV, respectively) as well as pET-28a-hCPX III and pET-
28a-hCPX IV (full-length human CPXs III and IV, respectively; all in the
pET-28a vector; Novagen).
Western blots
SDS-PAGE and immunoblotting were performed using standard proce-
dures. Immunoreactive proteins were visualized with ECL (Amersham
Biosciences). The following antibodies were used for Western blots: pAbs
to CPX I/II (1:3,000; Synaptic Systems GmbH), polyclonal antisera to
mCPX III (1:1,000), mCPX IV (1:1,000), and the mAb to synaptophysin 1
(1:10,000, Cl 7.2; Synaptic Systems GmbH).
Subcellular fractionation
Subcellular fractionations were prepared essentially as described previ-
ously (Jones and Matus, 1974). They were designated as follows: H, ho-
mogenate; P1, nuclear pellet; S1, supernatant after synaptosome sedi-
mentation; P2, crude synaptosomal pellet; LP1, lysed synaptosomal
membranes; S3, cytosolic fraction; P3, light membrane pellet; LS2, cyto-
solic synaptosomal fraction; LP2, crude synaptic vesicle fraction; and
SPM, synaptic plasma membranes.
Retinal tissue preparation and light microscopic immunocytochemistry
Adult mice were anesthetized deeply with halothane and decapitated. The
immunocytochemical labeling was performed by indirect fluorescence
(Brandstätter et al., 1999). Retinal sections were incubated in the primary
antibodies overnight at RT. In addition to the rabbit anti-CPX III (1:10,000)
and anti-CPX IV (1:40,000) pAbs produced and characterized in the
present study, the following antibodies were used: a rabbit anti-CPX I/II
pAb (1:1,000; Synaptic Systems GmbH), a guinea pig anti-VGLUT1 pAb
(1:50,000; CHEMICON International, Inc.), a mouse anti-Bassoon mAb
(1:2500; StressGen Biotechnologies), a guinea pig anti-GABA pAb (1:500;
CHEMICON International, Inc.), a rat anti-glycine pAb (1:1,000; gift of
D. Pow, University of Queensland, Brisbane, Australia), and a mouse anti-
PKC  mAb (1:200; Biodesign International). The binding sites of the pri-
mary antisera were revealed by secondary antisera, goat anti–rabbit,
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Alexa 594 (red fluorescence) or Alexa 488 (green fluorescence; diluted
1:500; Molecular Probes). In control experiments, either the primary or
secondary antiserum was omitted, resulting in a complete loss of specific
immunoreactivity. Sections were examined with a confocal laser scanning
microscope (Carl Zeiss MicroImaging, Inc.) equipped with an Ar laser
and a HeNe laser and a Plan-Neofluar 40 , NA 1.3 oil objective (LSM5
Pascal; Carl Zeiss MicroImaging, Inc.). High resolution scanning was per-
formed with 2,048   2,048 pixels. Projections of 3–5 optical slices (z-axis
step 0.48  m) are shown. Images were adjusted for contrast and bright-
ness using Adobe Photoshop 5.5, and figures were arranged using Corel
Draw 9. For PNA, cone synaptic terminals were labeled with fluorescein-
tagged PNA. The incubation solution was made up of PNA (Vector Labora-
tories) diluted 1:20 in 3% normal goat serum (wt/vol) and 1% BSA (wt/vol)
in PB. The incubation of the retinal sections with PNA was combined with
the incubation in the secondary antiserum against CPX III or CPX IV, goat
anti–rabbit IgG coupled to Alexa 594 (1:500; Molecular Probes).
Expression of recombinant proteins in HEK293 cells
Mammalian expression vectors encoding full-length wt rCPX I, rCPX II,
mCPX III, and mCPX IV with the EGFP sequence attached at their NH2
(CPXs III and IV) or COOH (CPXs I and II) termini were constructed in
pEGFP-C1 and pEGFP-N1 (CLONTECH Laboratories, Inc.), respectively.
The mCPX III-C156S and mCPX IV-C158S mutant constructs were gener-
ated from the full-length cDNAs using the QuikChange Site-Directed Mu-
tagenesis Kit (Stratagene) and sequenced. HEK293 cells were grown on
glass coverslips coated with 0.5% gelatin and transfected with EGFP ex-
pression vectors using the SuperFect transfection method (QIAGEN). After
incubation for 48 h cells were washed twice with ice-cold PBS, fixed with
4% PFA in PBS for 20 min at RT, mounted with Fluoromount-G and exam-
ined by fluorescence microscopy. Digital images were captured with an
LSM510 laser scanning microscope (20 /0.50 Plan-Neofluar objective;
Carl Zeiss MicroImaging, Inc.) using the LSM510 software. For Western
blot analyses the mentioned wt and mutated CPX cDNAs were cloned into
the pcDNA3-IRES-EGFP vector and the corresponding proteins were ex-
pressed in HEK293 cells. 1 d after transfection, cells were harvested and
homogenized in PBS. Soluble and membranous pools were separated by
centrifugation (346,000 gmax for 15 min).
Metabolic labeling of EGFP-CPX–fusion proteins with [
14C]mevalonic acid 
and immunoprecipitation
Metabolic labeling of EGFP-CPX–fusion proteins with [
14C]mevalonic acid
in HEK293 cells was performed as described previously (Collins et al.,
2000). After labeling, cells were washed with PBS, scraped into solubiliza-
tion buffer (150 mM NaCl; 10 mM Hepes/KOH, pH 7.4; 1 mM EGTA;
2 mM MgCl2; 1% Triton X-100; 0.2 mM PMSF; 1  g/ml aprotinin; and
0.5  g/ml leupeptin) and stirred on ice for 30 min. Insoluble material was
removed by centrifugation (346,000 gmax for 15 min). 1.5 ml of each su-
pernatant were incubated with 10  l of hCPX III and hCPX IV antiserum, re-
spectively (2 h at 4 C). After addition of 30  l bed volume of protein G
Sepharose (Amersham Biosciences) and incubation for 2 h at 4 C, the
beads were washed four times with solubilization buffer by centrifugation
and resuspension, resuspended in SDS-PAGE sample buffer, and analyzed
by SDS-PAGE and immunoblotting using an mAb to GFP (1:1,000; Roche).
Expression of recombinant proteins in neurons
Primary cultures of hippocampal neurons were prepared and transfected
as described previously (Dresbach et al., 2003). Cells were fixed with 4%
PFA (20 min, at 4 C). Antibodies to synaptophysin (Sigma-Aldrich),
TGN38 (BD Transduction Laboratories), and MAP2 (Sigma-Aldrich) were
applied in blocking solution at 1:100–1:500 dilutions including 10%
horse serum, 2% serum albumin, 5% sucrose, and 0.3% Triton X-100.
Coverslips were mounted using Mowiol and viewed using an axioplan
microscope (Carl Zeiss MicroImaging, Inc.) equipped with a SpotRT
cooled CCD camera (Visitron Systems). Objectives were a 20  PlanApo
0.75 NA, a 40  PlanNeofluar 1.30 NA oil and a 63  PlanApo 1.4 NA
oil. Analysis of digital images was performed using MetaVue software
(Visitron Systems).
Fusion proteins and cosedimentation assays
Recombinant fusion proteins consisting of GST in frame with rCPX I, mCPX
III, or mCPX IV were synthesized in E. coli using pGEX-KG expression con-
structs (Guan and Dixon, 1991). Recombinant proteins were purified on
glutathione agarose (Sigma-Aldrich) and used, immobilized on the resin,
for cosedimentation assays. Crude synaptosomes from rat brain and rat
retina homogenates were solubilized at a protein concentration of 2 mg/ml
in solubilization buffer (see protocol for metabolic labeling of CPXs
above). After stirring on ice for 10 min, insoluble material was removed
by centrifugation (10 min at 346,000 gmax and 4 C). The equivalent of 3 mg
of total protein was then incubated with 50  g of immobilized GST-fusion
protein and 5 mM DTT for 2 h at 4 C. Beads were washed once (short
wash) or three times with solubilization buffer containing 5 mM DTT and
0.1% Triton X-100, resuspended in SDS-PAGE sample buffer, and ana-
lyzed by SDS-PAGE and immunoblotting. The following antibodies were
used for immunodetection: mAbs to syntaxin 1 (1:10,000, Cl 78.2), syn-
aptobrevin 2 (1:10,000; Cl 69.1), and SNAP-25 (1:5,000; Cl 71.1, all
purchased from Synaptic Systems GmbH), and a polyclonal antiserum to
syntaxin 3 (1:1,000; Morgans et al., 1996).
Culture and electrophysiology of autaptic hippocampal neurons
Primary hippocampal neurons were prepared from newborn CPX I/II DKO
mice and grown on astrocyte microislands as described previously (Reim
et al., 2001; Rosenmund et al., 2002). For each experiment, approxi-
mately equal numbers of neurons from the respective groups were mea-
sured on the same DIV (9–14 DIV). Whole-cell patch clamp recordings
were performed 9–11 h after Semliki Forest Virus infection (Ashery et al.,
2000), as described previously (Rosenmund et al., 2002). Semliki Forest
Virus constructs were designed to encode the respective CPX, followed by
an IRES and the EGFP cDNA. This allowed us to identify infected cells and
to estimate the expression level of the constructs. The cellular EGFP expres-
sion levels were similar for all tested construct. Data are presented as
mean   standard error. Statistical significance of differences between two
groups was estimated by unpaired nonparametric t test.
Online supplemental material
Fig. S1 shows the cross reactivities of antibodies to CPX isoforms using
proteins from HEK293 cells transfected with CPX I-EGFP, CPX II-EGFP,
EGFP-CPX III, and EGFP-CPX IV. Fig. S2 shows the differential expression
of CPX I/II by amacrine cells. Fig. S3 shows the expression of CPX III by
amacrine and bipolar cells. Fig. S4 shows the distribution of EGFP-tagged
CPX proteins in HEK293 cells. Online supplemental material is available
at http://www.jcb.org/cgi/content/full/jcb.200502115/DC1.
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